Pharmafile Logo

Digital Therapeutics Landscape in Europe

September 3, 2020 |  

OPEN Health introduce an overview of regulatory and HTA developments for digital therapeutics in Europe focusing on Germany and the UK

Digital Therapeutics Landscape in Europe: The Case of Germany and the UK

The COVID-19 virus crisis has opened immense windows of opportunity in healthcare around the globe. One of the greatest opportunities is in digital health, and in particular, digital therapeutics (DTx). The need for continued medical care combined with social distancing has led to a spike in use of digital health tools worldwide.1 As the interest in and use of digital health has grown during this period, we anticipate that investments in digital health tools will continue to accelerate after the COVID-19 pandemic. When the COVID-19 outbreak started, millions of Chinese people turned to online doctors and online health tools1 to find the needed support for their health. While these developments could create new risks for privacy and data protection, they also represent an unprecedented opportunity to integrate industry 4.0 in healthcare for the benefit of patients.

HIGHLIGHTS INCLUDE:
  • Opportunities and threats of digital therapeutics after COVID-19
  • Digital therapeutics landscape in the European Union
  • Review and comparison of the German and UK therapeutics landscape
  • Develop game-changing insights and competitive advantage on both a global and local scalepi

Pink divider

Download the white paper and learn how it’s happening now!

Download the Paper- PMLiVE

  1. https://www.cnbc.com/2020/03/26/investments-in-digital-health-care-could-accelerate-after-coronavirus-credit-suisse-says.html

This content was provided by OPEN Health

Company Details

 Latest Content from  OPEN Health 

OPEN Health announces a new team of experts will lead its HEOR & Market Access Scientific Office

OPEN Health, a global provider of consultancy, HEOR and market access, and scientific communications services, announced a new team of experts will lead its HEOR & Market Access Scientific Office.

OPEN Health Appoints Richard Jones as President for Evidence & Access

OPEN Health is pleased to announce the appointment of Richard Jones as President for Evidence & Access.

Drive, Discover, Dive_OPEN Health

Learn how to unlock the power of simplicity in complex omnichannel healthcare communications.

Novel Oncology Therapies Require Innovative Methods in Oncology Modeling

Innovative methods in oncology modeling are needed to demonstrate the value of many new cancer treatments, including immuno-oncologic therapies.

The CM Group rebrands to OPEN Health

Following its acquisition by OPEN Health in 2022, The CM Group, a US healthcare agency offering a suite of solutions to the biotech and pharma industry, has undergone extensive rebranding...

OPEN Health to acquire leading US-based life science strategy and advisory firm Acsel Health

OPEN Health to acquire leading US-based life science strategy and advisory firm Acsel Health

OPEN Health Appoints David P. King as Non-Executive Chairman and Paul Carter as Independent Board Member

OPEN Health has announced additions to its board of directors, appointing David P. King as non-executive Chairman and Paul Carter as an independent board member.

Steve Chick joins OPEN Health as Chief Growth Officer for Evidence & Access

OPEN Health is pleased to announce the appointment of Stephen J. Chick as Chief Growth Officer for OPEN Health Evidence & Access.

OPEN Health to acquire leading US medical communications platform The CM Group from NaviMed Capital

OPEN Health, a pre-eminent global provider of scientific communications and market access services, announced that it signed a binding agreement to acquire The CM Group, a leading US domestic medical...

How digital health is changing the relationship between patients and health providers | OPEN Health

The pandemic has forced pharmaceutical industry to look at digital in a new way - and it’s driving better health outcomes